AstraZeneca Breast Cancer Drug Extends Progression-Free Survival

Source Summary

WILMINGTON, DE — AstraZeneca reported updated Phase III trial results showing its investigational breast cancer therapy camizestrant extended the time patients lived without disease progression and delayed the need for ...